Zobrazeno 1 - 10
of 840
pro vyhledávání: '"Se Hoon, Park"'
Autor:
Primo N. Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo Perini, Toni K. Choueiri, Robert J. Motzer
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-12 (2024)
Abstract Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective i
Externí odkaz:
https://doaj.org/article/f27c30f1bd8e406580492b76ee1bb216
Publikováno v:
eLife, Vol 13 (2024)
Establishing transepithelial ion disparities is crucial for sensory functions in animals. In insect sensory organs called sensilla, a transepithelial potential, known as the sensillum potential (SP), arises through active ion transport across accesso
Externí odkaz:
https://doaj.org/article/7a37e8996ded412c9fea3bc29c4a2c28
Autor:
Sung Hee Lim, Sung Wook Cho, Jae Hoon Chung, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Se Hoon Park
Publikováno v:
Journal of Urologic Oncology, Vol 22, Iss 1, Pp 29-33 (2024)
Purpose To assess the feasibility and short-term efficacy of maintenance enzalutamide following first-line docetaxel plus androgen deprivation therapy (ADT) in patients with high-volume, metastatic castration-naive prostate cancer (mCNPC). Materials
Externí odkaz:
https://doaj.org/article/59c2be82be10482ca9e0308e3952fac7
Publikováno v:
Journal of Urologic Oncology, Vol 22, Iss 1, Pp 59-67 (2024)
Purpose TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study aims to investigate the clinical and histopathological
Externí odkaz:
https://doaj.org/article/2fe6557cb5df4b0bbb51e8af9a54e08b
Autor:
Se Hoon Park, Sang Joon Shin, Sun Young Rha, Seung-Hoon Beom, Ho Kyung Seo, Bhumsuk Keam, Miso Kim, Yoon-Hee Hong, Shinkyo Yoon, Jae-Lyun Lee
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe JAVELIN Bladder 100 phase 3 trial demonstrated the efficacy and safety of avelumab administered as first-line (1L) maintenance treatment in patients with advanced urothelial carcinoma (UC) without disease progression after 1L platinum-b
Externí odkaz:
https://doaj.org/article/22b1cbb4ff8949a3841372b296121eb2
Autor:
Enrique Grande, Aristotelis Bamias, Matthew D. Galsky, Eiji Kikuchi, Ian D. Davis, José Ángel Arranz, Arash Rezazadeh Kalebasty, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Javier Puente, Jian-Ri Li, Sandrine Bernhard, Alan Nicholas, Julie Telliez, Maria De Santis
Publikováno v:
European Urology Open Science, Vol 58, Iss , Pp 28-36 (2023)
Standard-of-care first-line treatment for metastatic urothelial carcinoma (mUC) is platinum-based chemotherapy (CTx). Maintenance immunotherapy is a treatment option for patients without progressive disease (PD) after induction CTx. IMvigor130 was a
Externí odkaz:
https://doaj.org/article/23174f8611b2473d8705753cdcab834f
Autor:
Chung Un Lee, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Seong Il Seo, Seong Soo Jeon, Se Hoon Park, Byong Chang Jeong
Publikováno v:
Journal of Urologic Oncology, Vol 21, Iss 3, Pp 241-248 (2023)
Purpose Radical cystectomy (RC) is recommended for patients with non–muscle-invasive bladder cancer (NMIBC) who are unresponsive to intravesical bacillus Calmette-Guérin (BCG) instillation. However, RC is a very risky treatment, and some patients
Externí odkaz:
https://doaj.org/article/1ffc6ff6d7da48d49146c14d93d8bdec
Autor:
Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A. Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Yousef Zakharia, Keqin Qi, Sydney Akapame, Spyros Triantos, Anne O'Hagan, Yohann Loriot
Publikováno v:
European Urology Open Science, Vol 50, Iss , Pp 1-9 (2023)
Background: Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines of prior platinum-based chemotherapy. Objective: To bett
Externí odkaz:
https://doaj.org/article/859488fb49644ff6bbf4afa1b1012ee4
Publikováno v:
AIP Advances, Vol 13, Iss 5, Pp 055119-055119-8 (2023)
In advanced millimeter-wave packaging technology, signal loss is considered the main problem, which can be resolved using low-loss circuits for minimizing transmission losses. Herein, the radio frequency integrated circuit (RF-IC), an active element,
Externí odkaz:
https://doaj.org/article/4a247d6e6b3c46f49c9dbb28df482e08
Autor:
Sung Hee Lim, Jaeyun Jung, Jung Young Hong, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Kyoung-Mee Kim, Jeeyun Lee
Publikováno v:
Biomedicines, Vol 11, Iss 12, p 3264 (2023)
Purpose: Therapeutic targeting of RAF1 is a promising cancer treatment, but the relationship between clinical features and RAF1 aberrations in terms of the MAPK signaling pathway is poorly understood in various solid tumors. Methods: Between October
Externí odkaz:
https://doaj.org/article/9802d46e123e4ee38b6fc134ba6d3c77